Solifenacin succinateMuscarinic receptor antagonist CAS# 242478-38-2 |
- Resminostat hydrochloride
Catalog No.:BCC1888
CAS No.:1187075-34-8
- RG2833
Catalog No.:BCC1893
CAS No.:1215493-56-3
- Daminozide
Catalog No.:BCC1514
CAS No.:1596-84-5
- Tasquinimod
Catalog No.:BCC1987
CAS No.:254964-60-8
- CHAPS
Catalog No.:BCC1476
CAS No.:75621-03-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 242478-38-2 | SDF | Download SDF |
| PubChem ID | 443937 | Appearance | Powder |
| Formula | C27H32N2O6 | M.Wt | 480.55 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | YM905 | ||
| Solubility | H2O : 100 mg/mL (208.09 mM; Need ultrasonic) DMSO : ≥ 100 mg/mL (208.09 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;butanedioic acid | ||
| SMILES | C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5.C(CC(=O)O)C(=O)O | ||
| Standard InChIKey | RXZMMZZRUPYENV-DZSUWJOWSA-N | ||
| Standard InChI | InChI=1S/C23H26N2O2.C4H6O4/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19;5-3(6)1-2-4(7)8/h1-9,18,21-22H,10-16H2;1-2H2,(H,5,6)(H,7,8)/t21?,22-;/m0./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Solifenacin Succinate(YM905; Vesicare) is a muscarinic receptor antagonist.
IC50 value:
Target: muscarinic receptor
Solifenacin succinate (YM905; Vesicare) is a prescription medication used to treat certain bladder problems. References: | |||||
Solifenacin succinate Dilution Calculator
Solifenacin succinate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0809 mL | 10.4047 mL | 20.8095 mL | 41.619 mL | 52.0237 mL |
| 5 mM | 0.4162 mL | 2.0809 mL | 4.1619 mL | 8.3238 mL | 10.4047 mL |
| 10 mM | 0.2081 mL | 1.0405 mL | 2.0809 mL | 4.1619 mL | 5.2024 mL |
| 50 mM | 0.0416 mL | 0.2081 mL | 0.4162 mL | 0.8324 mL | 1.0405 mL |
| 100 mM | 0.0208 mL | 0.104 mL | 0.2081 mL | 0.4162 mL | 0.5202 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Solifenacin Succinate(YM905; Vesicare) is a muscarinic receptor antagonist.Solifenacin succinate (YM905; Vesicare) is a prescription medication used to treat certain bladder problems.
- Thalictrimine
Catalog No.:BCN5097
CAS No.:24240-04-8
- 3-Methyl-9H-carbazol-2-ol
Catalog No.:BCN4666
CAS No.:24224-30-4
- Mianserin
Catalog No.:BCC4134
CAS No.:24219-97-4
- Tabimorelin hemifumarate
Catalog No.:BCC5897
CAS No.:242143-80-2
- Farrerol
Catalog No.:BCN2481
CAS No.:24211-30-1
- 3,3',4,4'-Benzophenone tetracarboxylic dianhydride
Catalog No.:BCC8593
CAS No.:2421-28-5
- Bis(4-hydroxy-3-methylphenyl) sulfide
Catalog No.:BCC8885
CAS No.:24197-34-0
- Epiyangambin
Catalog No.:BCN7029
CAS No.:24192-64-1
- Boc-Glu-OH
Catalog No.:BCC3386
CAS No.:2419-94-5
- H-Glu(OtBu)-OH
Catalog No.:BCC2933
CAS No.:2419-56-9
- H-Lys(Boc)-OH
Catalog No.:BCC2982
CAS No.:2418-95-3
- Zoniporide dihydrochloride
Catalog No.:BCC7461
CAS No.:241799-10-0
- 2,5-Bis(4-aminophenyl)-1,3,4-oxadiazole
Catalog No.:BCC8501
CAS No.:2425-95-8
- H-Phe(4-Br)-OH
Catalog No.:BCC3157
CAS No.:24250-84-8
- H-Phe(4-I)-OH
Catalog No.:BCC3259
CAS No.:24250-85-9
- 7-Methoxy-8-Hydroxy-4-Phenylcoumarin
Catalog No.:BCC8292
CAS No.:24258-36-4
- Shikokianin
Catalog No.:BCN3278
CAS No.:24267-69-4
- Furanodienone
Catalog No.:BCN3010
CAS No.:24268-41-5
- Cannabidivarin
Catalog No.:BCN7536
CAS No.:24274-48-4
- Acetylcephalotaxine
Catalog No.:BCN5098
CAS No.:24274-60-0
- Sodium ferulic
Catalog No.:BCN8542
CAS No.:24276-84-4
- Boc-Glu-OtBu
Catalog No.:BCC3388
CAS No.:24277-39-2
- Mycophenolic acid
Catalog No.:BCC4803
CAS No.:24280-93-1
- Hesperidin methylchalcone
Catalog No.:BCN8125
CAS No.:24292-52-2
Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial.[Pubmed:27698559]
Clin Interv Aging. 2016 Sep 19;11:1301-1307.
OBJECTIVE: The objective of this study was to evaluate the safety and efficacy of tamsulosin hydrochloride 0.2 mg (TAM) and its combination with Solifenacin succinate 5 mg (SOL) after transurethral resection of the prostate (TURP). PATIENTS AND METHODS: The patients were randomized into three groups: TURP (group 1), TURP plus TAM (group 2), and TURP plus TAM + SOL (group 3). Patients in group 2 and group 3 received medication for 4 weeks. The primary efficacy end points were the mean change in total International Prostate Symptom Score (IPSS) and IPSS subscores. The secondary end points included quality-of-life score, Overactive Bladder Symptom Score, and short-form voiding and storage score of International Continence Society. RESULTS: In total, 37 men (31.8%) in group 1, 37 men (31.8%) in group 2, and 42 men (36.2%) in group 3 completed the study. In total IPSS, no significant improvement was seen from baseline to the end of treatment in groups 2 and 3 compared with group 1. However, in group 2, the decrement in the IPSS storage score was smaller than group 1 (P=0.02), and in group 3, the decrement in the IPSS voiding score was smaller than group 1 (P=0.05). In groups 2 and 3 compared with group 1, improvements in the quality of life score, total score of Overactive Bladder Symptom Score, and short-form voiding score and storage score of International Continence Society were not statistically significant. CONCLUSION: Treatment with TAM and combination of TAM and SOL did not have significant additional benefits for lower urinary tract symptoms during the early recovery period after TURP.
Long-term prospective study of the persistence of solifenacin succinate in previously untreated Japanese female patients with overactive bladder.[Pubmed:27520420]
Int J Urol. 2016 Oct;23(10):866-872.
OBJECTIVES: To prospectively evaluate the persistence of solifenacin treatment in previously untreated Japanese female patients with overactive bladder. METHODS: A total of 73 previously untreated Japanese female patients diagnosed with overactive bladder were given 5 mg of solifenacin once daily and prospectively followed for 3 years with periodic evaluations. The drug persistence rate was estimated using the Kaplan-Meier method. If solifenacin had to be terminated or a patient did not come to the hospital to receive a prescription, the reason was determined. RESULTS: After solifenacin treatment, the overactive bladder symptom score and average voided volume were significantly improved and maintained for 3 years. The 6-month, 1-year, 2-year and 3-year persistence rates were 50.7%, 41.1%, 32.9% and 23.3%, respectively. The major reasons for solifenacin therapy discontinuation were symptom resolution (27.4%) and adverse events (20.5%). Patients with nocturia three times or more at baseline had lower persistence than those with nocturia more than three times. Patients without detrusor overactivity at baseline had lower drug persistence than those with detrusor overactivity. CONCLUSIONS: Approximately one-quarter of previously untreated Japanese overactive bladder female patients continue solifenacin treatment for 3 years. Many patients discontinue solifenacin for various reasons, including symptom resolution and adverse events.
Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment.[Pubmed:28150436]
Low Urin Tract Symptoms. 2018 May;10(2):135-142.
OBJECTIVE: To evaluate the efficacy and safety of gabapentin in comparison to Solifenacin succinate and placebo for the treatment of adult patients with overactive bladder (OAB). METHOD: A 12-week, randomized, double-blind, double dummy placebo-controlled, clinical trial was conducted between October 2010 and August 2014 at a tertiary medical center. Eligible and consenting patients included were randomized into three treatment groups (placebo, gabapentin and solifenacin). After a 12-week treatment period, an intention to treat analysis was applied to assess between group differences on the micturitions and urgency episodes per 24 h; which were evaluated by 3-day micturition diary mean change from baseline to post treatment. Health related quality of life (HRQOL) domains were likewise assessed by OAB questionnaire (OAB-q). Adverse event were monitored and summarized. Study results were analyzed at statistical significance of 0.05. (ClinicalTrials.gov ID NCT01486706) RESULT: A total of 94 participants were included for end-study efficacy and safety analysis. Compared to placebo, gabapentin and solifenacin have statistically significant improvement in mean number of micturitions per 24 h (adjusted mean difference [AMD] -1.179, 95%CI -1.98, -0.38; P < 0.001; -1.706, 95%CI -2.52, -0.09; P < 0.001; respectively), and in mean number of urgency episodes per 24 h (AMD -0.903, 95%CI -1.44, -0.37; P < 0.001; -0.896, 95%CI -1.44, -0.35; P < 0.001). Gabapentin also demonstrated significant improvement over the solifenacin in the mean number of nocturia episodes/24 h (AMD -0.607, 95%CI -1.04, -0.18; P < 0.001). Adverse event related to gabapentin treatment was lesser than solifenacin, and comparable to placebo. CONCLUSION: Gabapentin treatment with acceptable safety profile, improves OAB symptoms and HRQOL domains.
